Use of GLP-1 Receptor Agonists in Men With Benign Prostatic Hyperplasia or Prostate Cancer
GLP-1 receptor agonists are not listed as contraindicated for benign prostatic hyperplasia (BPH) or prostate cancer in U.S. prescribing information for agents such as liraglutide. [1] Current evidence does not show an increased risk of incident prostate cancer with GLP-1 receptor agonist use in real-world comparative data. [2]
Contraindications Relevant to Prostate Disease
Liraglutide labeling contraindicates use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2). [1] No contraindication for BPH or prostate cancer appears in liraglutide prescribing information. [1]
Medication Selection Algorithm
Selection of a GLP-1 receptor agonist for indications such as type 2 diabetes or obesity is based on standard drug characteristics and patient comorbidities rather than prostate disease status. [1] Common GLP-1 receptor agonist options include:
- Liraglutide [1]
- Semaglutide [1]
- Dulaglutide [1]
- Exenatide [1]
- Tirzepatide (dual GIP/GLP-1 receptor agonist) [1]
Evidence on Prostate Cancer Incidence
A nationwide register-based cohort study in men aged ≥50 years (Denmark) compared GLP-1 receptor agonist users with basal insulin users and reported prostate cancer incidence rates of comparable magnitude. [2] In that study, the adjusted hazard ratio for incident prostate cancer with GLP-1 receptor agonist use was 0.91 (95% CI 0.73–1.14) in intention-to-treat analyses and 0.80 (95% CI 0.64–1.01) in per-protocol analyses. [2]
Evidence From Broader Cancer Incidence Analyses
In a retrospective cohort study of adults with obesity using electronic health record data (2014 to 2024), overall cancer risk was not increased with GLP-1 receptor agonist use versus nonuse. [3] That study included prostate cancer as one of 14 tracked cancer types. [3]
Clinical Approach for Men With Existing Prostate Cancer
Prostate cancer presence does not constitute a labeled reason to avoid GLP-1 receptor agonists based on MTC/MEN2-based contraindications. [1] Prostate cancer care should continue to follow standard oncology guidance with ongoing monitoring for prostate-specific disease outcomes. [1]
Common Pitfalls to Avoid
Prostate disease should not be treated as a GLP-1 receptor agonist contraindication without a labeled reason specific to the chosen agent. [1] Dose selection should not be based on assumptions of prostate cancer progression effects in the absence of supportive evidence. [2]
Targets and Goals of Therapy
The goal of GLP-1 receptor agonist therapy remains glycemic control and/or weight reduction as indicated, with adverse-event monitoring per product labeling rather than prostate-specific treatment targets. [1]